{"bill": {"#text": "\n\t", "form": {"current-chamber": {"#tail": "\n\t\t", "#text": "IN THE HOUSE OF REPRESENTATIVES"}, "#text": "\n\t\t", "congress": {"#tail": "\n\t\t", "#text": "113th CONGRESS"}, "#tail": "\n\t", "legis-num": {"#tail": "\n\t\t", "#text": "H. R. 5657"}, "official-title": {"#tail": "\n\t", "#text": "To amend the Federal Food, Drug, and Cosmetic Act to ensure that eligible product developers have\n\t\t\t competitive access to approved drugs and licensed biological products, so\n\t\t\t as to enable eligible product developers to develop and test new products,\n\t\t\t and for other purposes."}, "session": {"#tail": "\n\t\t", "#text": "2d Session"}, "distribution-code": {"#tail": "\n\t\t", "@display": "yes", "#text": "I"}, "action": {"action-date": {"#tail": "\n\t\t\t", "@date": "20140918", "#text": "September 18, 2014"}, "#tail": "\n\t\t", "action-desc": {"#tail": "\n\t\t", "#text": "\n        ", "committee-name": {"#tail": "\n      ", "@committee-id": "HIF00", "#text": "Committee on Energy and Commerce"}, "sponsor": {"#tail": " (for himself and ", "#text": "Mr. Stivers", "@name-id": "S001187"}, "cosponsor": {"#tail": ") introduced the following bill; which was referred to the ", "#text": "Mr. Welch", "@name-id": "W000800"}}, "#text": "\n\t\t\t"}, "legis-type": {"#tail": "\n\t\t", "#text": "A BILL"}}, "@bill-stage": "Introduced-in-House", "@bill-type": "olc", "@dms-id": "H4B1AFAC38C9A497C81B2BC7DC458C557", "@public-private": "public", "legis-body": {"#tail": "\n", "@style": "OLC", "section": [{"@section-type": "section-one", "#tail": "\n    ", "text": {"#tail": "\n\t\t", "#text": "This Act may be cited as the ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ".", "quote": [{"short-title": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "act", "#text": "Fair Access for Safe and Timely Generics Act of 2014", "@value": "Fair Access for Safe and Timely Generics Act of 2014", "@proposed": "true"}, "#text": "\n              "}, "#tail": " or the ", "#text": "\n          "}, {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "act", "#text": "FAST Generics Act of 2014", "@value": "FAST Generics Act of 2014", "@proposed": "true"}, "#text": "\n            "}], "@entity-type": "law-citation", "#text": "\n          "}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "1."}, "header": {"#tail": "\n      ", "#text": "Short title"}, "#text": "\n      ", "@id": "HFD47D1A12BAC427EA34726E0A8D58A42", "@commented": "no"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "#text": "Congress finds the following:", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "2."}, "header": {"#tail": "\n      ", "#text": "Findings"}, "paragraph": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " or ", "@entity-type": "act", "#text": "section 505(b)", "@value": "Food, Drug, and Cosmetic Act/s:505/ss:b"}, {"#tail": " (", "@entity-type": "act", "#text": "505(j) of the Food, Drug, and Cosmetic\n\t\t\t Act", "@value": "Food, Drug, and Cosmetic Act/s:505/ss:j"}, {"#tail": ") and under ", "@entity-type": "uscode", "#text": "355(j)", "@value": "usc/21/355/j"}], "#text": "Reference product license or approval holders are restricting competitive access to reference\n\t\t\t products by sponsors seeking to develop drugs, generic drugs, and\n\t\t\t biosimilars under ", "external-xref": {"#tail": " and ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "21 U.S.C. 355(b)(2)", "@value": "usc/21/355/b/2"}, "@parsable-cite": "usc/21/355", "#text": "\n            ", "@legal-doc": "usc"}, "{http://namespaces.cato.org/catoxml}entity": {"#tail": ". These restrictions are deterring and\n\t\t\t delaying development of generic drugs and biosimilars by extending lawful\n\t\t\t patent-based monopolies beyond their lawful patent life.", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 351 of the Public\n\t\t\t Health Service Act", "@value": "Public Health Service Act/s:351"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "42 U.S.C. 262", "@value": "usc/42/262"}, "@parsable-cite": "usc/42/262", "#text": "\n            ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n        ", "#text": "(1)"}, "@id": "HFB43C92ED2D64F29B7F6B98B18B9C84E", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "The enforcement provisions set forth in ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " have not been sufficient to prevent\n\t\t\t anti-competitive practices that interfere with access to reference\n\t\t\t products which is necessary for the timely development of affordable\n\t\t\t generic drugs and biosimilars.", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 505\u20131(f)(8) of the Federal Food, Drug, and Cosmetic\n\t\t\t Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505\u20131/ss:f/p:8"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "21 U.S.C. 355\u20131(f)(8)", "@value": "usc/21/355\u20131/f/8"}, "@parsable-cite": "usc/21/355-1", "#text": "\n            ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n        ", "#text": "(2)"}, "@id": "HBA23909267764747BC86D305FD2217AE", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "The opinion in Verizon Communications Inc. v. Law Offices of Curtis V. Trinko, LLP, 540 U.S. 398\n\t\t\t (2004) should not be construed to impair or bar the application of the\n\t\t\t antitrust\n\t\t\t laws consistent with the provisions of this Act."}, "enum": {"#tail": "\n        ", "#text": "(3)"}, "@id": "HAC67E70100BC4CA8A99508817F65002C", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " or ", "@entity-type": "act", "#text": "section 505(b)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:b"}, {"#tail": " (", "@entity-type": "act", "#text": "505(j) of the Federal Food, Drug, and\n\t\t\t Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:j"}, {"#tail": "), and ", "@entity-type": "act", "#text": "355(j)", "@value": "Public Health Service Act/s:355/ss:j"}], "#text": "There is not a regulatory structure in place that is sufficient to deter or remedy the\n\t\t\t anti-competitive harm that results when access to reference brand products\n\t\t\t is restricted to sponsors developing drugs, generic drugs, and biosimilars\n\t\t\t in accordance with ", "external-xref": {"#tail": " and ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "21 U.S.C. 355(b)(2)", "@value": "usc/21/355/b/2"}, "@parsable-cite": "usc/21/355", "#text": "\n            ", "@legal-doc": "usc"}, "{http://namespaces.cato.org/catoxml}entity": {"#tail": ", respectively.", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 351 of the\n\t\t\t Public Health Service Act", "@value": "Public Health Service Act/s:351"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "42 U.S.C. 262", "@value": "usc/42/262"}, "@parsable-cite": "usc/42/262", "#text": "\n            ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n        ", "#text": "(4)"}, "@id": "H9EC77238385D441D86289E75BF4688BD", "#text": "\n        "}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "#text": "Requiring license holders to comply with requirements for competitive access to their products, and\n\t\t\t subjecting license holders to antitrust liability for failing to do so,\n\t\t\t will not impose obligations on the courts that they cannot adequately and\n\t\t\t reasonably adjudicate.", "italic": {"#tail": "\n        "}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(5)"}, "@id": "H06FF2EF313C3472D91F30B8EC8B9DB3C", "#text": "\n        "}], "#text": "\n      ", "@id": "HC38DEC13BA844EF4AF61BEFE38C0E9BD"}, {"#tail": "\n  ", "enum": {"#tail": "\n      ", "#text": "3."}, "header": {"#tail": "\n\t\t\t", "#text": "Competitive access to covered products for development purposes"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": [{"#tail": " is amended by inserting after\n\t\t\t ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Chapter V of the Food Drug and Cosmetic Act", "@value": "Food Drug and Cosmetic Act/ch:V"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "21 U.S.C. 351 et seq.", "@value": "usc/21/351/etseq"}, "@parsable-cite": "usc/21/351", "#text": "\n            ", "@legal-doc": "usc"}}, {"#tail": " the following new section:", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 505\u20131 of such Act", "@value": "Food Drug and Cosmetic Act/s:505\u20131"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "21 U.S.C. 355\u20131", "@value": "usc/21/355\u20131"}, "@parsable-cite": "usc/21/355-1", "#text": "\n            ", "@legal-doc": "usc"}}], "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "In general"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n        ", "#text": "."}, "#tail": "\n\t\t\t", "section": {"#tail": "\n          ", "enum": {"#tail": "\n            ", "#text": "505\u20132."}, "header": {"#tail": "\n\t\t\t\t\t\t", "#text": "Competitive access to covered products for development purposes"}, "subsection": [{"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "In this section:", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(a)"}, "header": {"#tail": "\n              ", "#text": "Definitions"}, "paragraph": [{"#tail": "\n              ", "@id": "H609DAE322B594821B1D31D406066F0E2", "enum": {"#tail": "\n                ", "#text": "(1)"}, "header": {"#tail": "\n                ", "#text": "Covered product"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", including\u2014", "@entity-type": "act", "#text": "section\n\t\t\t 351 of the Public Health Service Act", "@value": "Public Health Service Act/s:351"}, "term": {"#tail": " means any drug approved under section 505 or any biological product that is licensed under ", "#text": "covered product"}, "#text": "The term ", "@display-inline": "yes-display-inline"}, "#text": "\n                ", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "any combination thereof; and"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@id": "H22C6E76FA01742C6997268FC9830B801", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", or ", "@entity-type": "act", "#text": "section 505", "@value": "Federal Food, Drug, and Cosmetic Act/s:505"}, {"#tail": " (as applicable), any product, including any device, that is\n\t\t\t marketed or intended for use with such drug or biological product.", "@entity-type": "act", "#text": "section 351 of the Public Health\n\t\t\t Service Act", "@value": "Public Health Service Act/s:351"}], "#text": "when reasonably necessary to demonstrate sameness, biosimilarity, or interchangeability for\n\t\t\t purposes of this section, ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "@id": "HBC9391851992487E80D8C44E0D65DA57", "#text": "\n                  "}]}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " or ", "@entity-type": "act", "#text": "section\n\t\t\t 505(b)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:b"}, {"#tail": " or the licensing of a biological product under ", "@entity-type": "act", "#text": "505(j)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:j"}, {"#tail": ".", "@entity-type": "act", "#text": "section\n\t\t\t 351 of the Public Health Service Act", "@value": "Public Health Service Act/s:351"}], "term": {"#tail": " means a person that seeks to develop an application for the approval of a drug under ", "#text": "eligible product developer"}, "#text": "The term ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(2)"}, "header": {"#tail": "\n                ", "#text": "Eligible product developer"}, "#text": "\n                ", "@id": "H16E0E40E05DC45489154386DF1DF5B30"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " or ", "@entity-type": "act", "#text": "section 505(b)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:b"}, {"#tail": " or a license\n\t\t\t under ", "@entity-type": "act", "#text": "section 505(j)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:j"}, {"#tail": " for a covered product\n\t\t\t (including the holder\u2019s agents, wholesalers, distributors, assigns, and\n\t\t\t corporate affiliates).", "@entity-type": "act", "#text": "section 351 of the Public Health Service Act", "@value": "Public Health Service Act/s:351"}], "term": {"#tail": " means the holder of an application approved under ", "#text": "license holder"}, "#text": "The term ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(3)"}, "header": {"#tail": "\n                ", "#text": "License holder"}, "#text": "\n                ", "@id": "H357EE5BC7321453D883FED9761E79D39", "@commented": "no"}, {"#tail": "\n            ", "@id": "H264AC1CB8F8242649B960D7DAFC430B6", "enum": {"#tail": "\n                ", "#text": "(4)"}, "header": {"#tail": "\n                ", "#text": "REMS product"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "term": {"#tail": " means a covered product that\u2014", "#text": "REMS product"}, "#text": "The term ", "@display-inline": "yes-display-inline"}, "#text": "\n                ", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "; or", "@entity-type": "act", "#text": "section 505\u20131", "@value": "Federal Food, Drug, and Cosmetic Act/s:505\u20131"}, "#text": "is subject to a risk evaluation and mitigation strategy under "}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@id": "H3218061F2B234CF483C0DA97EA8DB58C", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " to have\n\t\t\t in effect an approved risk evaluation and mitigation strategy under\n\t\t\t ", "@entity-type": "act", "#text": "section 909(b) of the Food and Drug Administration Amendments Act of 2007", "@value": "Food and Drug Administration Amendments Act of 2007/s:909/ss:b"}, {"#tail": ".", "@entity-type": "act", "#text": "section 505\u20131", "@value": "Federal Food, Drug, and Cosmetic Act/s:505\u20131"}], "#text": "is deemed under "}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "@id": "H24792686979240CD947A670749600A5D", "#text": "\n                  "}]}], "#text": "\n              ", "@id": "H285B5A7F594B45259729B29A12669895"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", respectively, the ", "@entity-type": "act", "#text": "section 505 of this Act or section 351 of the Public\n\t\t\t Health Service Act", "@value": "Public Health Service Act/s:505"}, {"#tail": " shall require that the\n\t\t\t covered product\u2019s license holder not adopt, impose, or enforce any\n\t\t\t condition relating to the sale, resale, or distribution of the covered\n\t\t\t product, including any condition adopted, imposed, or enforced as an\n\t\t\t aspect of a risk evaluation and mitigation strategy approved by the\n\t\t\t ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ", that restricts or has the effect of restricting the supply of\n\t\t\t such covered product to an eligible product developer for development or\n\t\t\t testing purposes.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "As a condition of approval or licensure, or continuation or renewal of approval or licensure, of a\n\t\t\t covered product under ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(b)"}, "header": {"#tail": "\n              ", "#text": "Competitive access to covered products as a condition on approval or licensing"}, "#text": "\n              ", "@id": "HCA12802BDF3E4628BF0194D3467E3129", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "#text": "No license holder shall adopt, impose, or enforce any condition relating to the sale, resale, or\n\t\t\t distribution of a covered product that interferes with or restricts access\n\t\t\t to reasonable quantities of a covered product by an eligible product\n\t\t\t developer for development and testing purposes, at commercially\n\t\t\t reasonable, market-based prices, from the license holder or from any\n\t\t\t wholesaler or specialty distributor authorized by the license holder to\n\t\t\t commercially distribute or sell the covered product ", "italic": {"#tail": "unless the license holder generally adopts, imposes, or enforces lawful conditions relating to the\n\t\t\t sale, resale, or distribution of a covered product, with respect to other\n\t\t\t buyers of the covered product.", "#text": "\n\t\t\t\t\t\t\t\t"}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(c)"}, "header": {"#tail": "\n              ", "#text": "Competitive access to covered products other than REMS products for development purposes"}, "#text": "\n              ", "@id": "H52CF29A3DEDA4997931A045944E875BE"}, {"#tail": "\n            ", "enum": {"#tail": "\n              ", "#text": "(d)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Competitive access to REMS products for development purposes"}, "paragraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall prohibit or restrict, or be construed or applied to\n\t\t\t prohibit or restrict, the supply of such REMS product to an eligible\n\t\t\t product developer for development and testing purposes, at commercially\n\t\t\t reasonable, market-based prices, from the REMS product\u2019s license holder or\n\t\t\t from any wholesaler or specialty distributor authorized by the license\n\t\t\t holder to commercially distribute or sell the REMS product.", "@entity-type": "act", "#text": "section 505\u20131", "@value": "Federal Food, Drug, and Cosmetic Act/s:505\u20131"}, "#text": "With respect to a REMS product, no aspect of a risk evaluation and mitigation strategy under\n\t\t\t ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(1)"}, "header": {"#tail": "\n                ", "#text": "Prohibited use of REMS to restrict access"}, "#text": "\n                ", "@id": "HC49AC1468ED84D219F9E0A897234AFB1"}, {"#tail": "\n            ", "@id": "H06E97D15ACE745A3A60E12994D36738B", "enum": {"#tail": "\n                ", "#text": "(2)"}, "header": {"#tail": "\n                ", "#text": "Single, shared system of elements to assure safe use"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "With respect to a REMS product, no license holder shall take any step that impedes\u2014"}, "#text": "\n                ", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "; or", "@entity-type": "act", "#text": "section\n\t\t\t 505\u20131", "@value": "Federal Food, Drug, and Cosmetic Act/s:505\u20131"}, "#text": "the prompt development of a single, shared system of elements to assure safe use under "}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@id": "H424D1101343A48D383598DF095F372D3", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "the entry on commercially reasonable terms of an eligible product developer into a previously\n\t\t\t approved system of elements to assure safe use."}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "@id": "HCAB7CEFE44954CDBB36071C68BFC3A55", "#text": "\n                  "}]}], "#text": "\n              ", "@id": "HD2AE88927D4641DCACDA222C7BEF236D"}, {"#tail": "\n            ", "enum": {"#tail": "\n              ", "#text": "(e)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Procedures for obtaining access to covered products"}, "paragraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Notwithstanding any other provision of law, in the case of an eligible product developer that has\n\t\t\t an authorization to obtain a covered product in effect under paragraph (2)\n\t\t\t or (3), no license holder shall adopt, impose, or enforce any other\n\t\t\t condition relating to the sale, resale, or distribution of such covered\n\t\t\t product that interferes with or restricts access to reasonable quantities\n\t\t\t of the covered product by the eligible product developer for development\n\t\t\t and testing purposes, at commercially reasonable, market-based prices,\n\t\t\t from the license holder or from any wholesaler or specialty distributor\n\t\t\t authorized by the license holder to commercially distribute or sell the\n\t\t\t covered product, unless the license holder generally adopts, imposes, or\n\t\t\t enforces lawful conditions relating to the sale, resale, or distribution\n\t\t\t of a covered product, with respect to other buyers of the covered product.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(1)"}, "header": {"#tail": "\n                ", "#text": "Competitive access"}, "#text": "\n                ", "@id": "HEA3F9F79304141528E6666AF84CF7BF6"}, {"#tail": "\n              ", "@id": "HA71B636A4D3A40AC888C44F9AAEFE915", "enum": {"#tail": "\n                ", "#text": "(2)"}, "header": {"#tail": "\n                ", "#text": "General covered products authorization"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ".\n\t\t\t Within 60 days after receiving such a request, the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " shall, by\n\t\t\t written notice, issue such authorization if\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "Any eligible product developer may seek a general covered products authorization, authorizing the\n\t\t\t eligible product developer to obtain any covered product for the purposes\n\t\t\t of development and testing, by making a written request to the "}, "#text": "\n                ", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "the eligible product developer holds one or more approved applications or licenses for a covered\n\t\t\t product or, in the absence of such approvals or licensures, otherwise\n\t\t\t establishes that the eligible product developer can comply with the\n\t\t\t requirements of this Act and other applicable law for the development and\n\t\t\t testing of covered products; and", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@id": "H9F5DA53093774D5D865005DC08CB647E", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " does not find that the eligible product developer has materially failed to comply\n\t\t\t with the requirements of this Act or other applicable law for the\n\t\t\t development and testing of covered products.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "@id": "H2AF3EF6CB51744BABF2E5A81EFD6F6AF", "#text": "\n                  "}]}, {"#tail": "\n              ", "@id": "H15ADFCE7503041BA8B05AD5703BA02B1", "enum": {"#tail": "\n                ", "#text": "(3)"}, "header": {"#tail": "\n                ", "#text": "Individual covered product authorization"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ". Within 60 days of receiving such a request, the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": "\n\t\t\t shall, by written notice, issue such authorization for purposes of\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "Any eligible product developer may seek an authorization to obtain an individual covered product\n\t\t\t for development and testing purposes by making a written request to the\n\t\t\t ", "@display-inline": "yes-display-inline"}, "#text": "\n                ", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n\t\t\t determines necessary; or", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "development and testing that does not involve human clinical trials, if the eligible product\n\t\t\t developer has agreed to comply with any conditions the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@id": "H1FFF8D5706764A0EA4E90B7D0AD16C1C", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "testing that involves human clinical trials if the eligible product developer has submitted a\n\t\t\t protocol for testing that includes protections that will provide an\n\t\t\t assurance of safety comparable to the assurance of safety provided by any\n\t\t\t distribution restrictions governing the approval or licensure of the\n\t\t\t covered product or the license holder\u2019s distribution of the covered\n\t\t\t product.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "@id": "H14698E52FDCB42BEBF34182DACD2F862", "#text": "\n                  "}]}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " having taken\n\t\t\t final action on the request for authorization, the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " shall be\n\t\t\t deemed to have issued, by written notice, the requested authorization.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "If the 60-day period referred to in paragraph (2) or (3) expires without the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(4)"}, "header": {"#tail": "\n                ", "#text": "Failure by Secretary to take final action"}, "#text": "\n                ", "@id": "H903E56EC69D546A7909E98DE27C4C8FC"}, {"#tail": "\n            ", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "If an eligible product developer is unable, for purposes of development and testing, to obtain\n\t\t\t reasonable quantities of a covered product commercially, either from the\n\t\t\t license holder or from any wholesaler or specialty distributor authorized\n\t\t\t by the license holder to commercially distribute or sell the covered\n\t\t\t product, any eligible product developer that has obtained authorization to\n\t\t\t do so, in accordance with paragraph (2) or (3), shall be entitled to\n\t\t\t obtain such reasonable quantities of such covered product at the same\n\t\t\t commercially reasonable, market based price on which such reasonable\n\t\t\t quantities of such covered product have been previously sold by the\n\t\t\t license holder to third parties in the open market. Such eligible product\n\t\t\t developer shall initiate its acquisition of such covered product by\n\t\t\t providing a written request for specific quantities of such covered\n\t\t\t product either\u2014", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "clause": [{"@indent": "up1", "#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "to any wholesaler or specialty distributor authorized by the license holder to commercially\n\t\t\t distribute or sell the covered product; or", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "#text": "\n                    ", "@id": "H111B92FDE40041E488F2154205B207E7"}, {"@indent": "up1", "#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "in the event no such wholesaler or specialty distributor has been designated for such purpose by\n\t\t\t the license holder, to the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "#text": "\n                    ", "@id": "H6DDB24F87A6E4110B3C774B50E0F0B3C"}], "header": {"#tail": "\n                  ", "#text": "Process for obtaining product pursuant to an authorization"}, "@display-inline": "yes-display-inline", "#text": "\n                  ", "@id": "H90D85AD3E85C4583AE93FDFE67534F83", "@commented": "no"}, {"@indent": "up1", "#tail": "\n                ", "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "the eligible product developer has, or is deemed to have, a general covered products authorization\n\t\t\t under paragraph (2); or", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "@id": "HD75BED155F324A6BBF25859A538B4FB9", "#text": "\n                    "}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "the eligible product developer has, or is deemed to have, an authorization under paragraph (3) to\n\t\t\t obtain the specific covered product.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "@id": "HAB174570FD894B6CB77A18A0AE7E81F6", "#text": "\n                    "}], "enum": {"#tail": "\n                  ", "#text": "(B)"}, "header": {"#tail": "\n                  ", "#text": "Request contents"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "Such request shall include a statement regarding the quantity of covered product sought for\n\t\t\t development or testing purposes, and state that either\u2014", "@display-inline": "yes-display-inline"}, "#text": "\n                  ", "@id": "HED604D1445AA46F88F6DFE0825806499"}, {"@indent": "up1", "#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "In the event that a request is made to a wholesaler or specialty distributor under this paragraph,\n\t\t\t the wholesaler or specialty distributor shall not disclose to the license\n\t\t\t holder of the covered product involved the identity of the eligible\n\t\t\t product developer, but may disclose to such license holder, only if\n\t\t\t required to do so by the holder\u2014", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(C)"}, "header": {"#tail": "\n                  ", "#text": "Disclosure of information by wholesalers and specialty distributors"}, "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "the fact that a request has been made;"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "#text": "\n                    ", "@id": "H71963706510D461285FE5EA19139BD3A", "@commented": "no"}, {"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "the dates on which the request was made and fulfilled;"}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "#text": "\n                    ", "@id": "H08FEF2AFFF2E4915B6E2F7342C3011A1", "@commented": "no"}, {"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "the commercial terms on which the request was fulfilled; and"}, "enum": {"#tail": "\n                    ", "#text": "(iii)"}, "#text": "\n                    ", "@id": "HA80D7B584FF54A88B898E6CCA151A547", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "the quantity of the covered product furnished by the wholesaler or specialty distributor in\n\t\t\t compliance with the request."}, "enum": {"#tail": "\n                    ", "#text": "(iv)"}, "#text": "\n                    ", "@id": "H866F4A142C70411D892EE5E2CC644286", "@commented": "no"}], "#text": "\n                  ", "@id": "H8C1383EA2BE64B7FB86AE115FD83740D", "@commented": "no"}, {"@indent": "up1", "#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " under this subsection, then the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": "\n\t\t\t shall, within 5 business days of receipt of the request, notify the\n\t\t\t license holder that a request for such covered product has been made, and\n\t\t\t the quantity of the covered product requested, and such license holder\n\t\t\t shall, within 30 days after receiving notice from the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ", provide\n\t\t\t the quantity of the requested covered product, through means specified by\n\t\t\t the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ", at a non-discriminatory, commercially reasonable,\n\t\t\t market-based price for which such covered product has been previously sold\n\t\t\t by the license holder (or any wholesaler or specialty distributor\n\t\t\t authorized by the license holder to commercially distribute or sell the\n\t\t\t covered product) to third parties in the open market. The means\n\t\t\t established by the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " under this clause shall not disclose to the\n\t\t\t license holder the identity of the eligible product developer that has\n\t\t\t requested quantities of the covered product for development and testing\n\t\t\t purposes.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "In the event that a request is made to the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(D)"}, "header": {"#tail": "\n                  ", "#text": "Disclosure pursuant to means specified by Secretary"}, "#text": "\n                  ", "@id": "H3D6D727157E14E91979317883114964B"}, {"@indent": "up1", "#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " may prohibit, limit, or otherwise suspend a transfer of a covered\n\t\t\t product to an eligible product developer if the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " determines that\n\t\t\t the transfer of such product to the eligible product developer would\n\t\t\t present an imminent hazard to the public health. In such cases, the\n\t\t\t ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " shall specify the basis for the determination, including the\n\t\t\t specific information available to the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " which served as the basis\n\t\t\t for such determination, and confirm such determination in writing.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "At any time, the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(E)"}, "header": {"#tail": "\n                  ", "#text": "Imminent hazard"}, "#text": "\n                  ", "@id": "H1A48BF1F49874596AC75D42E3644DA74"}], "enum": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "(5)"}, "@id": "H9C13C818D2D44C4EB11C7A0677FBCFF4", "#text": "\n                "}], "#text": "\n              ", "@id": "HD6D3CECFA02E48ADAAE43AD6367AB85A"}, {"#tail": "\n            ", "enum": {"#tail": "\n              ", "#text": "(f)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Public and private enforcement"}, "paragraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", a violation of a requirement or\n\t\t\t prohibition in subsection (b), (c), (d)(1), (d)(2), or (e)(1) shall be\n\t\t\t treated in the case of a REMS product, as a violation of the product\u2019s\n\t\t\t risk evaluation and mitigation strategy.", "@entity-type": "act", "#text": "Public Health Service Act", "@value": "Public Health Service Act"}, "#text": "For purposes of this Act and the "}, "enum": {"#tail": "\n                ", "#text": "(1)"}, "header": {"#tail": "\n                ", "#text": "Application of certain provisions"}, "#text": "\n                ", "@id": "H6491237105EE41DC9B3AC1CA370C139E", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " under subsection (e) and that is aggrieved by a violation of\n\t\t\t subsection (b), (c), (d)(1), (d)(2), or (e)(1) by a license holder or any\n\t\t\t wholesaler or specialty distributor authorized by the license holder to\n\t\t\t commercially distribute or sell the covered product may sue such license\n\t\t\t holder for injunctive relief and treble damages (including costs and\n\t\t\t interest of the kind described in ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "An eligible product developer that has authorization for access to a covered product from the\n\t\t\t ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ").", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "section 4(a) of the Clayton Act", "@value": "Clayton Act/s:4/ss:a"}, {"#tail": ")", "@entity-type": "uscode", "#text": "15\n\t\t\t U.S.C. 15(a)", "@value": "usc/15/15/a"}], "@entity-type": "law-citation", "#text": "\n                    "}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(2)"}, "header": {"#tail": "\n                ", "#text": "Remedies"}, "#text": "\n                ", "@id": "H7A6F347A39C847D8B994BE03183BEBFB"}], "#text": "\n              ", "@id": "HE02FC531ED2C4CE9A1948C53B5958A62", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "#text": "The holder of an approved application or license for a covered product shall not be liable for any\n\t\t\t claim arising out of an eligible product developer\u2019s development or\n\t\t\t testing activities conducted under this section, including a claim arising\n\t\t\t out of a failure of the eligible drug developer to follow adequate\n\t\t\t safeguards to assure safe use of the covered product.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(g)"}, "header": {"#tail": "\n              ", "#text": "Limitation of liability"}, "#text": "\n              ", "@id": "HD1FBD96793624D6DAB25227D41EFE4AD"}, {"#tail": "\n          ", "enum": {"#tail": "\n              ", "#text": "(h)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Reports"}, "paragraph": [{"#tail": "\n              ", "@id": "H9657337A107B44AF8ECB41293469C75C", "enum": {"#tail": "\n                ", "#text": "(1)"}, "header": {"#tail": "\n                ", "#text": "Report by FDA"}, "text": {"short-title": {"#tail": ", and annually thereafter, the ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                  ", "@entity-type": "act", "#text": "Fair Access for Safe and Timely Generics Act of 2014", "@value": "Fair Access for Safe and Timely Generics Act of 2014", "@proposed": "true"}, "#text": "\n                    "}, "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", acting through the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ", shall\n\t\t\t submit to ", "@entity-type": "federal-body", "#text": "Commissioner of Food and Drugs", "@entity-id": "7524"}, {"#tail": " a report that\u2014", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}], "#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Not later than 180 days after the enactment of the ", "@display-inline": "yes-display-inline"}, "#text": "\n                ", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "identifies each instance of noncompliance by any license holder with a requirement or prohibition\n\t\t\t in subsection (b), (c), (d)(1), (d)(2), or (e)(1); and", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@id": "H80714725630E4593A4DF6687FD0E982F", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " to remedy such noncompliance and to enforce such\n\t\t\t requirements and prohibitions, whether by assessment of a penalty or\n\t\t\t otherwise.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "describes the actions taken by the "}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "@id": "H808ACB0EC9684DBFBE1A20D595E26D3E", "#text": "\n                  "}], "@commented": "no"}, {"#tail": "\n            ", "@id": "H0ED8C93608C94FA7B2A4A1FB4CE5DDF8", "enum": {"#tail": "\n                ", "#text": "(2)"}, "header": {"#tail": "\n                ", "#text": "Report by FTC"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"@proposed": "true", "#tail": ", and annually thereafter, the ", "@entity-type": "act", "@value": "Fair Access for Safe and Timely Generics Act of 2014", "short-title": {"#tail": "\n                  ", "#text": "Fair Access for Safe and Timely Generics Act of 2014"}, "#text": "\n                    "}, {"#tail": " shall submit to ", "@entity-type": "federal-body", "#text": "Federal Trade Commission", "@entity-id": "2900"}, {"#tail": " a report that\u2014", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}], "#text": "Not later than 270 days after the enactment of the ", "@display-inline": "yes-display-inline"}, "#text": "\n                ", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " pertaining to the withholding of competitive\n\t\t\t access to covered products, the actions taken by the ", "@entity-type": "federal-body", "#text": "Commission", "@entity-id": "2900"}, {"#tail": " with\n\t\t\t respect to each such complaint, and the result of each such ", "@entity-type": "federal-body", "#text": "Commission", "@entity-id": "2900"}, {"#tail": "\n\t\t\t action; and", "@entity-type": "federal-body", "#text": "Commission", "@entity-id": "2900"}], "#text": "describes the complaints received by the "}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@id": "H1AF9C87D51EB44E083E675E49A5175BB", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "examines the impact on the market entry of competing drug products, and the pricing and\n\t\t\t availability of such products, in the United States resulting from\n\t\t\t noncompliance by license holders with a requirement or prohibition in\n\t\t\t subsection (b), (c), (d)(1), (d)(2), or (e)(1).", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "@id": "H5490C3F7145041279C93D6784F36FEFC", "#text": "\n                  "}], "@commented": "no"}], "#text": "\n              ", "@id": "H10EF251BA99F43AD92A8DCDA74BE8981", "@commented": "no"}], "#text": "\n            ", "@id": "H379EA604454049F18AD2EE90DBC778BD"}, "@display-inline": "no-display-inline", "#text": "\n\t\t\t\t\t", "@id": "H0916A6E1349E42D997A3D972F3E0DF9E"}, "#text": "\n        ", "@id": "HDE051360CFC2494EA778953E4AECE5FC"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended by adding at the\n\t\t\t end the following:", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 301 of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:301"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "21 U.S.C. 331", "@value": "usc/21/331"}, "@parsable-cite": "usc/21/331", "#text": "\n            ", "@legal-doc": "usc"}}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Prohibited act"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n        ", "#text": "."}, "#tail": "\n\t\t\t", "subsection": {"#tail": "\n          ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (including its contractors, assigns, or corporate affiliates)) of\n\t\t\t a requirement or prohibition in ", "@entity-type": "act", "#text": "section\n\t\t\t 505\u20132(a)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505\u20132/ss:a", "@proposed": "true"}, {"#tail": ", ", "@entity-type": "act", "#text": "subsection (b)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505\u20132/ss:b", "@proposed": "true"}, {"#tail": ", ", "@entity-type": "act", "#text": "(c)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505\u20132/ss:c", "@proposed": "true"}, {"#tail": ", ", "@entity-type": "act", "#text": "(d)(1)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505\u20132/sch:d/p:1", "@proposed": "true"}, {"#tail": ", or\n\t\t\t ", "@entity-type": "act", "#text": "(d)(2)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505\u20132/sch:d/p:2", "@proposed": "true"}, {"#tail": " (relative to competitive access to covered\n\t\t\t products for development purposes).", "@entity-type": "act", "#text": "(e)(1) of section 505\u20132", "@value": "Federal Food, Drug, and Cosmetic Act/s:505\u20132/sch:e/p:1", "@proposed": "true"}], "#text": "Any violation by the license holder of a covered product (as such terms are defined in ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n            ", "#text": "(ddd)"}, "#text": "\n            ", "@id": "H42311CD5CBCA444F93AC7C55339CEA6B", "@commented": "no"}, "@display-inline": "no-display-inline", "#text": "\n\t\t\t\t\t", "@id": "H557C72FD942E47ADB401F4663051E7BC"}, "#text": "\n        ", "@id": "H1A19F68E763049D8BF773CADF78399B2", "@commented": "no"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is\n\t\t\t amended\u2014", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 505\u20131(i)(1)(B) of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505\u20131/ss:i/p:1/sp:B"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "21 U.S.C. 355\u20131(i)(1)(B)", "@value": "usc/21/355\u20131/i/1/B"}, "@parsable-cite": "usc/21/355-1", "#text": "\n            ", "@legal-doc": "usc"}}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(c)"}, "header": {"#tail": "\n        ", "#text": "Waiver of single, shared system requirement"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "quote": {"#tail": " at the end;", "#text": "or"}, "#text": "in clause (i), by striking "}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "H987A17A6F4C34E09BCD332B8B8B9BC08", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "quote": {"#tail": "; and", "#text": "; or"}, "#text": "in clause (ii), by striking the period at the end and inserting "}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "HF1319E1732714A3E8F76860759BE8A30", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "by adding at the end the following:"}, "enum": {"#tail": "\n          ", "#text": "(3)"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n          ", "#text": "."}, "#tail": "\n\t\t\t\t", "clause": {"#tail": "\n            ", "text": {"#tail": "\n            ", "#text": "the applicant for an abbreviated new drug application certifies that it attempted in good faith to\n\t\t\t create or negotiate entry into a single, shared system, but was unable to\n\t\t\t finalize commercially reasonable terms with the holder of the listed drug\n\t\t\t within 120 days, and such certification includes a description of the\n\t\t\t efforts made by the applicant for the abbreviated new drug application to\n\t\t\t create or negotiate entry into a single, shared system.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(iii)"}, "#text": "\n              ", "@id": "HE4AFFB20DE53422DBFD43D33B4A1BCB2", "@commented": "no"}, "@display-inline": "no-display-inline", "#text": "\n\t\t\t\t\t\t", "@id": "HC9E92FAD776148DD9852D04DAEF89384"}, "#text": "\n          ", "@id": "HC5F21EE3746C44478EBBA98C046530E7"}], "#text": "\n        ", "@id": "H32F63F5CF7EE429B8DABC253639876F7", "@commented": "no"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ",\n\t\t\t as added by this section) regardless of whether those applications or\n\t\t\t licenses were approved before, on, or after the date of enactment of this\n\t\t\t Act.", "@entity-type": "act", "#text": "section 505\u20132(a) of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505\u20132/ss:a", "@proposed": "true"}, "#text": "This section and the amendments made by this section shall take effect upon enactment, and shall\n\t\t\t apply to all approved applications or licenses for a covered product (as\n\t\t\t defined in ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(d)"}, "header": {"#tail": "\n        ", "#text": "Effective date"}, "#text": "\n        ", "@id": "H4FB5325E310C44C9860C50D395C48E6A", "@commented": "no"}], "#text": "\n      ", "@id": "H4DC28075102142AAA1E62B5CCDEA8009"}], "#text": "\n\t\t", "@id": "HE7123CEC06004969AFF4D473E38237D9"}, "metadata": {"#tail": "\n", "dublinCore": {"{http://purl.org/dc/elements/1.1/}date": {"#tail": "\n", "#text": "2014-09-18"}, "{http://purl.org/dc/elements/1.1/}format": {"#tail": "\n", "#text": "text/xml"}, "{http://purl.org/dc/elements/1.1/}language": {"#tail": "\n", "#text": "EN"}, "#tail": "\n", "{http://purl.org/dc/elements/1.1/}title": {"#tail": "\n", "#text": "113 HR 5657 IH: FAST Generics Act of 2014"}, "{http://purl.org/dc/elements/1.1/}rights": {"#tail": "\n", "#text": "Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain."}, "{http://purl.org/dc/elements/1.1/}publisher": {"#tail": "\n", "#text": "U.S. House of Representatives"}, "#text": "\n"}, "#text": "\n"}}}